Navigation Links
Samaritan's Alzheimer's Drug Caprospinol Suggests Brain May be Able,to Heal From Alzheimer's Disease


Animal Study Confirms Caprospinol's (SP-233) Ability to Clear Brain Plaque and Empower Rat Brain Cells to Recover Memory Function

In Vivo 'Proof of Concept' Study Proposes Direct Correlation Between Removing Beta Amyloid Plaque and Memory Recovery

LAS VEGAS, July 10, 2007 (PRIME NEWSWIRE) -- Samaritan Pharmaceuticals Inc. (AMEX:LIV), a developer of innovative drugs, is pleased to announce it has confirmed Caprospinol's (SP-233) efficacy in its ability to dramatically decrease beta amyloid plaque in the brain, accompanied by a complete recovery of memory back to baseline (p=0.002), as shown in a Morris water maze task. This study confirms previously reported in-vitro data and suggests Caprospinol may not only slow down Alzheimer's but may also reverse plaque-related brain injuries associated with the mind-robbing disease of Alzheimer's.

The hallmark of Alzheimer's disease is plaque formation in areas of the brain that control memory and thinking skills. Plaque can cause swelling and bumps on nerve cells, making it hard or even impossible for the cells to communicate. While the cause of Alzheimer's disease still remains unknown, a growing number of researchers are indicating that plaque formation and accumulation may play a role.

The study was conducted by Samaritan's collaborating researchers, including Dr. Laurent Lecanu and Dr. Vassilios Papadopoulos.

Abstract:

www.samaritanpharma.com/caprospinol_abstract.pdf

Dr. Janet Greeson, CEO of Samaritan Pharmaceuticals stated, "Memory recovery in rats is a lot simpler than curing Alzheimer's disease in people but these study results are extremely encouraging. The rats tested with our proprietary Alzheimer's rat model took on features similar to the crippling dementia seen in a human's Alzheimer's brain, and then, by treating the rats with Caprospinol, the rat's brain cells bounced back with complete memory."

Samaritan Pharmaceuticals: "Transforming Today's Science Into Tomorrow's Cures..."

Samaritan Pharmaceuticals is a life science company focused on commercializing innovative drugs to relieve the suffering of patients with Alzheimer's, Cancer, Heart disease, and Infectious disease. Samaritan's business strategy is to partner its later stage drugs after Phase II (proof of concept) human studies and has executed its first partnership for its PII, HIV drug SP-01A, with Pharmaplaz, Ireland. Samaritan's Alzheimer's drug Caprospinol has received investigational new drug (IND) status from the FDA and Samaritan has several other drugs it is advancing to enter (IND) status. In addition, Samaritan's sales arm has acquired the marketing and sales rights to sell ten revenue-generating products in various Eastern European countries.

Website, http://www.samaritanpharma.com. Please register so we can notify you of upcoming conference calls, news and events.

The Samaritan Pharmaceuticals Inc. logo is available at http://www.primenewswire.com/newsroom/prs/?pkgid=2670

Disclaimer

The company disclaims any information that is created by an outside party and endorses only information that is communicated by its press releases, filings, and Website. This news release contains forward-looking statements that reflect management's current beliefs about the potential for its drug candidates, science, and technology. However, as with any biopharmaceutical under development, there are significant risks and uncertainties in the process of development and regulatory review. There are no guarantees that products will prove to be commercially successful. For additional information about the factors that affect the company's business , please read the company's latest Form 10-K filed April 13, 2007. The company undertakes no duty to update forward-looking statements.

-0- CONTACT: Samaritan Pharmaceuticals, Inc. Richard Brown (702) 735-7001 RichardBrown@SamaritanPharma.com


'"/>




Related medicine technology :

1. Resveratrol Studies Suggest Broad Implications for SIRT1 Activation in Neurodegenerative Diseases of Aging Such as Alzheimers Disease
2. Accera, Inc. Announces Open-Label Data from Phase II Study in Alzheimers Disease at International Conference on Prevention of Dementia
3. At the 2007 Alzheimers Association International Conference on the Prevention of Dementia - Neurochems U.S. Principal Investigator Presents Update on Tramiprosate (Alzhemed)
4. Myriad Genetics Presents Mathematical Comparison of Disease Modification Trial Designs at Alzheimers ConferenceCurrent Flurizan Phase 3 Study Design May Demonstrate Disease Modification
5. Treating Heart Disease Risk Factors May Slow Alzheimers Disease Progression
6. Medivations Dimebon Maintains Statistically Significant Benefit on All Five Efficacy Endpoints in Alzheimers Disease Trial After One Year of Therapy
7. Clinical Update - Debio 9902 (ZT-1) for Alzheimers Disease
8. Medivation to Host Conference Call to Discuss Top-Line 12-Month Results From Dimebon Alzheimers Disease Study
9. Medivation Announces Presentation of New Subset Analyses From Dimebon Phase 2 Alzheimers Disease Trial at American Academy of Neurology Annual Meeting
10. Ceregene Presents Interim Phase 1 Clinical Data of CERE-110 for the Treatment of Alzheimers Disease
11. Samaritan Announces Positive Data in Nonclinical (IND) In-Vitro Studies for Promising Alzheimers Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... -- The blood testing market in China ... and The Freedonia Group in a recent report.  The ... healthcare research firm said that China ... and in improving testing at the provincial level.   The ... Blood Testing Market in China , which utilized ...
(Date:4/28/2016)... 2016   Acsis , a leading provider of ... market research and advisory firm IDC has named it ... Worldwide Pharmaceutical Track and Trace Software 2016 Vendor Assessment ... assessment of the capabilities and business strategies of 10 ... Logo - http://photos.prnewswire.com/prnh/20160427/360791LOGO ...
(Date:4/27/2016)... 2016 Im ... Zürich gab Strekin AG den Start einer ... Erhaltung des Resthörvermögens von Patienten, denen ein ... umfassende Phase-II-Doppelblindstudie mit Placebo-Kontrollgruppe werden momentan Patienten ... während der Operation direkt ins Mittelohr verabreicht. ...
Breaking Medicine Technology:
(Date:5/2/2016)... ... May 02, 2016 , ... Dr. Rassouli, dentist in ... cognitive decline. According to the research, which was published in the “Journal of the ... decline, and about 5.4 million Americans have Alzheimer’s disease. The study found that dental ...
(Date:5/2/2016)... Boston, MA (PRWEB) , ... May 02, 2016 , ... ... and tips when trying to conceive. , “If you are ready to ... Dr. Mache Seibel. “My book, HealthChequesTM: Journal Babies is your Personal Conception & ...
(Date:5/2/2016)... ... ... Kulbersh of Carolina Facial Plastics isn’t surprised that Charlotte, NC, the city where he and ... Cities with the Highest Plastic Rates .” The other cities that made the list ... a survey by RealSelf and combining that data with the number of board-certified ...
(Date:5/2/2016)... Beach, FL (PRWEB) , ... May 02, 2016 , ... ... to great pain and suffering. With no cure, most patients must deal with prescription ... a free coupon card, allowing up to 75% savings at the pharmacy on many ...
(Date:5/2/2016)... ... May 02, 2016 , ... ... which includes amniotic fluid/“stem cells” and Platelet Rich Plasma (PRP) injections. “These are ... said Dr. James Baranski, D.C., of Advanced Spine & Sport Medical. “We are ...
Breaking Medicine News(10 mins):